Qiagen N.V. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (25)

Latest Posts

About This Stock More About This Stock
Week In Review: Beigene Sets Record With $1.4 Billion Celgene Deal
Article By: ChinaBio® Today
Saturday, July 8, 2017 2:35 PM EST
BeiGene of Beijing has entered a "transformational" collaboration with Celgene which involves BeiGene's clinical-stage PD-1 immuno-oncology drug, has a total value of almost $1.4 billion.
In this article: CELG, QGEN, BGNE, BYSI, ATNX
Read
Week In Review: Ping An Announces $1 Billion Fin-Tech/Healthcare VC Fund
Article By: ChinaBio® Today
Saturday, May 6, 2017 5:13 PM EST
Ping An Insurance Group, China's largest insurer by market value, announced plans to launch a $1 billion international fund that will invest in fin-tech and healthcare startups. Ping An is already a player in the fin-tech area with Lufax.
In this article: SRNE, QGEN
Read
New Stocks On Most Attractive/Most Dangerous: January 2017
Article By: David Trainer
Friday, January 13, 2017 10:20 AM EST
Our Most Attractive stocks have high and rising returns on invested capital and low price to economic book value ratios. Most Dangerous stocks have misleading earnings and long growth appreciation periods implied by their market valuations.
In this article: HAS, QGEN Also: VOXX, DLTR, FRAN, IDCC
Read
Illumina Misses Revenue Forecast Causing Collateral Damage To Biotechs
Article By: Rod Raynovich
Tuesday, October 11, 2016 11:00 PM EST
Illumina shares crashed 25% to $139, after a warning on third quarter sales. The global leader in DNA sequencing systems warned that revenues missed forecast and would be $607M, well short of earlier guidance of $625-$630M.
In this article: TMO, RHHBY, IBB, ILMN, PACB, QGEN, XBI, XLV, FMI
Read
Biotech ETFs Lead Q3 Rally: XBI Breaks Out
Article By: Rod Raynovich
Thursday, September 22, 2016 8:00 PM EST
The biotech sector is doing much better since BREXIT in late June despite a sell-off in late August. We are still trying to escape a bear market mentality because of the Q1 correction and concerns about drug prices.
In this article: AGN, JNJ, MDT, CPHD, ILMN, REGN, AMGN, BIIB, CELG, GILD, QGEN, XBI, XLV, Q, SRPT, BLUE, TSRO, IONS
Read

PARTNER HEADLINES

Latest Tweets for $QGEN

No tweets yet!